A common sequela to allogeneic or autologous bone marrow transplantation (BMT) is a delay in the reconstitution of a functional B-cell immune response. Therefore, we examined whether the posttransplant BM microenvironment is deficient in supporting the proliferation and/or differentiation of B-cell precursors. BM stromal cell cultures were established from patients who received allogeneic or autologous BMT for acute lymphoblastic leukemia, Hodgkin's disease, or non-Hodgkin's lymphoma. These cuttures were then compared with normal donor BM stromal cell cultures for expression of adhesion molecules and the capacity to support the adhesion and interleukin-7 (IL7)-dependent growth of normal B-cell precursors. Analysis of BM stromal cell cultures established from 28 BMT recipients showed a significantly reduced expression of cell surface vascular cell adhesion molecule-l (VCAM-l/CDlOG), compared with nor-LYMPHOPOIESIS occurs exclusively in the bone marrow (BM) of adult mammals and requires the regulated processing of developmental signals from both cellular and extracellular matrix components in the BM microenvironment. BM stromal cells, a complex array of nonhematopoietic fixed tissue cells in the medullary cavity, play a crucial role in murine B-cell development.'" The development of a long-term murine BM culture that supports the growth of early B-lineage cells has facilitated analyses of stromal cell f~nction.~ We have developed an in vitro BM stromal cell culture that supports the interleukin-7 (IL-7)-dependent growth of normal human B-cell precursor^.^ Recent studies have shown that CD19+/CD34+ pro-B cells are the 1L-7-responsive cells in our BM stromal cell culture, whereas CD19+/CD34-pre-B cells are completely nonresponsive to IL-7.' Our human BM culture, and similar cultures developed by all exhibit an absolute dependency of Bcell precursor growth on an intact BM stromal cell microenvironment.
A common sequela to allogeneic or autologous bone marrow transplantation (BMT) is a delay in the reconstitution of a functional B-cell immune response. Therefore, we examined whether the posttransplant BM microenvironment is deficient in supporting the proliferation and/or differentiation of B-cell precursors. BM stromal cell cultures were established from patients who received allogeneic or autologous BMT for acute lymphoblastic leukemia, Hodgkin's disease, or non-Hodgkin's lymphoma. These cuttures were then compared with normal donor BM stromal cell cultures for expression of adhesion molecules and the capacity to support the adhesion and interleukin-7 (IL7)-dependent growth of normal B-cell precursors. Analysis of BM stromal cell cultures established from 28 BMT recipients showed a significantly reduced expression of cell surface vascular cell adhesion molecule-l (VCAM-l/CDlOG), compared with nor-LYMPHOPOIESIS occurs exclusively in the bone marrow (BM) of adult mammals and requires the regulated processing of developmental signals from both cellular and extracellular matrix components in the BM microenvironment. BM stromal cells, a complex array of nonhematopoietic fixed tissue cells in the medullary cavity, play a crucial role in murine B-cell development.'" The development of a long-term murine BM culture that supports the growth of early B-lineage cells has facilitated analyses of stromal cell f~nction.~ We have developed an in vitro BM stromal cell culture that supports the interleukin-7 (IL-7)-dependent growth of normal human B-cell precursor^.^ Recent studies have shown that CD19+/CD34+ pro-B cells are the 1L-7-responsive cells in our BM stromal cell culture, whereas CD19+/CD34-pre-B cells are completely nonresponsive to IL-7.' Our human BM culture, and similar cultures developed by all exhibit an absolute dependency of Bcell precursor growth on an intact BM stromal cell microenvironment.
Several studies have found that the primary adhesive interaction between B-cell precursors and BM stromal cells is mediated by very late antigen-4 (VLA-4, also designated CD49dKD29) and vascular cell adhesion molecule-l (VCAM-I, also designated CD106), re~pectively.~-" Miyake et a1'0.'2 reported that monoclonal antibody (MoAb) to CD106 and CD49dCD29 inhibit the outgrowth of murine lymphoid cells in long-term BM cultures. Mouse MoAb to the CD49d and CD29 subunits of human VLA-4 inhibit the growth of terminal transferase+ human lymphoid progenit o r~.~ However, Kaisho et all3 reported that anti-CD106 failed to inhibit the growth of the murine pre-B cell line DW34 on human SV40 transformed BM stromal cell lines known to express CD106.
Given the importance of an intact BM stromal cell microenvironment for sustaining normal murine B lymphopoiesis,*.* we were interested in developing a strategy to evaluate the role of BM stromal cells during human B-cell ontogeny. TO achieve this goal, we characterized the B-lymphopoietic supportive capabilities of BM stromal cells isolated from patients undergoing BM transplantation (BMT). Our study was motivated by the well-known B-cell immune deficiency that is frequently present in recipients of allogeneic and autologous BMTt4 (and references therein). The kinetics of immune reconstitution post-BMT exhibit a general pattern: CD8' cytotoxic T cells, monocytes, and neutrophils reach normal numbers in peripheral blood within 1 month, whereas CD4' helper T cells and B cells are more delayed in appearance.I4 B-cell dysfunction in the early (3 months) post-BMT period has been attributed to increased T-cell suppression, decreased T-cell help, or failure to recapitulate B-cell ontogeny because of chronic graft-versus-host d i~e a s e .~~-~~ Notwithstanding the insight provided by these studies, the mechanism underlying the profound reduction in circulating B cells during the early post-BMT period has not been elucidated. The results in the current study define heretofore unidentified deficiencies in the capacity of BM stromal cells derived from BMT recipients to support the adhesion and growth of B-cell precursors.
DITTEL AND LEBIEN
with the guidelines of the University of Minnesota Committee on the Use of Human Subjects in Research. CD10f/CD19'Aight chain-B-cell precursors were isolated from human fetal BM using magnetic bead depletion, as previously described."
Adult BM stromal cells were established from normal donors."
Briefly, normal adult BM was centrifuged on Ficoll-Hypaque gradients (Sigma Chemical CO, St Louis, MO). Then, 10 to 40 x lo6 interface cells were cultured in individual T75 tissue culture flasks containing 10 mL of EX-CELL 320 (JRH Biosciences, Lenexa, KS) supplemented with 10% fetal calf serum (FCS), 100 units/mL penicillin, and 100 pglmL streptomycin. The adherent stromal cells reached confluence in 7 to 14 days and were passaged twice in EX-CELL 320/10% FCS. At this point, we had typically generated four to nine T75 flasks of normal donor BM stromal cells in approximately 40 days. Normal donor BM stromal cells were used at second or third passage. Transplant BM stromal cell cultures were initiated from BM aspirates (2 to 10 mL) obtained from individuals receiving autologous or allogeneic BMT for B-cell precursor-acute lymphoblastic leukemia (BCP-ALL), Hodgkin's disease (HD), or non-Hodgkin's lymphoma (NHL). The conditioning regimens and posttransplant therapies administered to these patients are described elsewhere.22.z3 BM aspirates were obtained at 21 or 28 days post-BMT from all patients. Recent analysis of the cellularity of these day 2l/day 28 post-BMT marrows indicates that they contain from 1% to 100% of the nucleated cell concentration of normal donor BM. BM was washed twice in RPM1 1640/2% FCS (Hyclone, Ogden, UT), and the cellular components were plated into a T25 tissue culture flask containing EX-CELL 320/20% FCS. Nonadherent cells were washed off 1 to 3 days later. Adherent cells were maintained in EX-CELL 320/ 20% FCS and monitored for growth by light microscopy. Cultures exhibiting growth initially appeared as foci of adventitial reticular cells that underwent expansion to near confluence within 7 to 14 days. The adherent cell contents of T25 flasks were then expanded into individual T75 flasks containing EX-CELL 320120% FCS. Once the stromal cells reached confluence (7 to 14 additional days), they were passaged twice using txypsiniEDTA. At this point, we had typically generated four to nine 'I75 flasks of transplant BM stromal cell cultures in approximately 54 days. Successfully established second or third passage transplant BM stromal cell cultures were maintained in EX-CELL 320/0% FCS without morphological changes or loss of viability, for greater than 6 months.
Stromal cell cultures were successfully established from 27 BMT patients, referred to by unique patient numbers (UPN . Of the 27 cultures, 15 were from patients with BCP-ALL (UPN 1-15), 8 were from NHL (UPN 16-23), and 4 were from HD (UPN 24-27). Eleven BCP-ALL patients received allogeneic BMT and 4 received autologous BMT, all 8 NHL patients received autologous BMT, and 1 HD patient received allogeneic BMT and 3 received autologous BMT. All 27 BMT stromal cell cultures were evaluated for expression of VCAM-I/CD106. However, logistical problems precluded evaluation of all 27 for the capacity to support adhesion and growth of B-cell precursors.
Anribodies and cytokines. The adhesion molecules recognized by MoAb in the current study have several different designations. For purposes of continuity, we will use the CD nomenclature throughout. Therefore, PECAM-1 = CD31, H-CAM = CD44, JCAM-I = CD54, VCAM-1 = CD106, the a subunit of LFA-I = CDlla, the 8 2 subunit of LFA-I = CD18, the a1 subunit of VLA-1 = CD49a. the a 2 subunit of VLA-2 = CD49b, the a 3 subunit of VLA-3 = CD49c. the a 4 subunit of VLA-4 = CD49d, the a 5 subunit of VLA-5 = CD49e, the a 6 subunit of VLA-6 = CD49f, the @l subunit of VLA-1-6 = CD29 and the a subunit of the vitronectin receptor = CD51. The VLA-4, VLA-S, and LFA-I heterodimers will be referred to as CD49dCD29, CD49e/CD29, and CD1 laICD18, respectively. 4B9/anti-CD10624 and LB2/anti-CD54" were gifts from Drs John Flow cytometry. Expression of cell surface molecules on BM stromal cells was analyzed by indirect immunofluorescent staining and flow cytometry, as previously described." BM stromal cells from normal donors and transplant recipients were dissociated from tissue culture flasks using Cell Dissociation Solution (Sigma Chemical CO). This nonenzymatic solution does not disrupt epitopes recognized by the MoAb used to characterize the stromal cells. Stromal cells were stained for the expression of CD10, CD29, CD31, CD34, CD44, CD49a-f, CD5 1, CD54, CD106, Class I major histocompatibility complex (MHC) and class 11 MHC using saturating concentrations of MoAb, counterstained with F(ab'), goat antimouse IgG-FITC, and fixed in 1% paraformaldehyde before analysis on a FACScan (Becton Dickinson, San Jose, CA) using CONSORT 30 software. Negative controls included mouse IgG,, IgGZ., or IgGZh myeloma proteins, Data are reported as percent positive cells or mean channel fluorescence (MCF) of 5,000 cells analyzed on a log scale. The influence of cytokines on BM stromal cell CD106 and CD54 expression was conducted as previously described."
Adhesion assay. Adhesion of CDlO'ilight chain-B-cell precursors to normal and transplant BM stromal cells was performed as previously described." Briefly, 50,000 Naz "CrO, radiolabeled CDlO'Aight chain-cells were incubated with normal or transplant BM stromal cells in the presence or absence of blocking MoAb for 2 hours at 37°C. After two washes to remove nonadherent cells, the stromal cell adherent B-cell precursors were quantitated on a ycounter. Each experimental variable was tested in replicates of eight. Percent B-cell precursor adherence was calculated as follows:
B-cell precursor growth assay. B-cell precursors were cultured in vitro as previously described: with the following modifications. Normal or transplant BM stromal cells were seeded onto 96-well flat-bottom microtiter plates at 3,000 cells per well in EX-CELL 320/10% FCS. After 3 days, the medium was switched to X-VIVO 1010% FCS and maintained until further use ( 2 to 4 days). Normal B-cell precursors were seeded onto normal or transplant BM stromal cells at approximately 20,000 to 40,000 cells per well in X-VIVO 10/0% FCS containing 10 ng/mL IL-7. The cultures were fed every For personal use only. on October 22, 2017. by guest www.bloodjournal.org From BONE MARROW STROMAL CELL VCAM-1 5 days with fresh X-VIVO 10/0% FCS containing 10 ndmL IL-7. CD19+ B-cell precursors were quantitated on days 0, 7, 14, and 21 by harvesting the cellular contents of the microtiter wells with Cell Dissociation Solution (Sigma) and stained for expression of CD19 using Leu-12-PE or 25C1-PE. For each condition, the cellular contents from 12 microtiter wells were pooled in groups of three wells, to provide four replicate data points. Polystyrene 6.0 micron microspheres (Polysciences, Inc. Warrington, PA) were used to quantify cell numbers using the F A C S C~~? .~'
Statistics. Statistical significance was determined
by the unpaired Student's t-test using Statworks (Cricket Software, Philadelphia, PA). Linear regression analysis and Pearson's correlation coefficient were determined using Cricket Graph (Cricket Software).
RESULTS
Transplant BM stromal cells express lower levels of CD104 compared with normal BM stromal cells. B-cell precursor/BM stromal cell adhesive interactions mediated by CD49dCD29 and CD106 regulate the in vitro adhesion and growth of normal B-cell precursors in human^'^^^" and ~c e .~n .~2 Therefore, we reasoned that an alteration in the expression and/or function of CD106 on BM stromal cells after BMT may help explain the delayed appearance of peripheral blood B cells so frequently observed posttrans-BM aspirates from 73 BMT recipients were collected on day +21 or +28 posttransplant, and cultured as described in Materials and Methods. Stromal cell cultures were successfully established from 27 patients (see Materials and Methods). No correlation was observed between the success or failure in establishing transplant BM stromal cell cultures relative to the hematopoietic disorder, type of transplant (allogeneic or autologous), age of the recipient, or number of remissions patients had experienced at the time their marrows were cultured.
We compared the CD106 fluorescence intensity on BM stromal cells established from 12 normal donors and 27 BMT recipients. As shown in Fig lA, the mean CD106 MCF on normal BM stromal cells was 23.4 9.8 (range, 5 to 36), whereas the mean CD106 MCF on transplant BM stromal cells was 14.8 5 8.7 (range, 2 to 38). This difference was significant (P < .Ol). In contrast, Fig 1B shows that the CD54 MCF on normal BM stromal cells was 6.7 2 4.7 (range, 2 to 18), whereas the CD54 MCF on transplant BM stromal cells was 6.8 t 5.7 (range, 0 to 26). Even though the transplant BM stromal cells analyzed had a statistically significant reduction in the intensity of CD106 expression, their expression of CD10, CD29, CD44, CD49a, CD49b, CD49c, CD49e, CD51, and class I MHC was indistinguishable from normal BM stromal cells (data not shown).
CD106 cell surface expression on normal BM stromal cells exhibited minor fluctuation as a function of time in culture, but expression was essentially unchanged for periods up to 4 months in serum-free medium (data not shown). regulated by TGF-D." The cytokine regulated increase or decrease in CD106 led to a corresponding increase or decrease in the adhesion of B-cell precursors.'' The data in Table I show that treatment of normal and transplant BM stromal cells with IL-ID and IL-4 leads to an increase in CD106 expression, and an increase in B-cell precursor adhesion. Conversely. incubation of normal BM stromal cells with TGF-/3 leads to a reduction in CD106 expression and a corresponding decrease in B-cell precursor adhesion. Evaluation of the effect of TGF-D on transplant BM stromal cells was compromised by the decreased CD106 expression present on the majority of transplant BM stromal cells ( Table  1 and Fig 1 ) .
Using MoAb to a panel of adhesion molecules, we showed that B-cell precursor adhesion to transplant BM stromal cells was mediated by CD49d/CD29 and CD1 06 (data not shown), comparable to our earlier studies with normal BM stromal cells."
Trurlsplant BM strond cells from n subset of patients .show CI reduced cnpacih to support tire in vitro proliferation of B-cell precursors. We used an IL-7/BM stromal cell culture to examine the capacity of transplant BM stromal cells to support the in vitro growth of normal B-cell precursors. As shown in Table 2 ,8 of the 19 transplant BM stromal cell cultures examined exhibited a reduced capacity to support B-cell precursor proliferation (<90% of control BM stromal cells at all three timepoints, and a mean < 80%).
The remaining 1 1 transplant BM stromal cell cultures supported the in vitro growth of B-cell precursors similar to normal stromal cells (>90% of control stroma for at least one time point, and a mean > 80%). Statistical comparison of the 8 cultures with reduced supportive capacity (mean ? SD = 66.2% ? 6.8%) to the 1 1 cultures with normal supportive capacity (mean ? SD = 89.6% ? 5.9%) showed a P value of < .OOl (unpaired t-test). The reduced support of Bcell precursor growth observed with some transplant BM stromal cells could not be explained by simple differences in plating densities of the BM stromal cells. When normal BM stromal cells were seeded at densities of 6,000, 3,000, 1,500, or 750 cells/well, similar numbers of CD19' cells were recovered from each culture 14 days later (data not shown).
Adhesion of B-cell precur.sors is correlated to the expression of CDl06, but not CD54, on transplant BM stromal cells. We have previously reported" and demonstrated in plant BM stromal cells parallels the cytokine regulated expression of CD106. Linear regression analysis comparing the level of cell surface CD106 expression by transplant BM stromal cells with the ability of the same stromal cells to support the adhesion of B-cell precursors showed a linear relationship (Fig 3A, R = . 638, P = .006). In contrast, no linear relationship was observed between B-cell precursor adhesion and CD54 expression (Fig 3B, R = . 152, P = S73). Abbreviations: ALL-acute lymphoblastic leukemia; NHL, non-Hodgkin's lymphoma; HD, Hodgkin's disease; ALLO-allogeneic, AUTO-autologous.
Expression of CD106 on transplant BM stromal cells is correlated to the level of IL-7-induced B-cell precursor
Values represent the percentage of CD19' B-lineage cells recovered from transplant BM stromal cells compared with the number of CD19' B-lineage cells recovered from normal BM stromal cells. The percentage was derived by dividing the absolute CD19' cell number recovered on transplant stromal cells bythe absolute CD19'cell number recovered on normal stromal cells. The mean value is the average of the three time points.
t Values defined as having a reduced capacity to support the in vitro growth of CD19' B-cell precursors (<go% of control stromal cells at all three timepoints and a mean of <EO%).
proliferation. Because the in vitro proliferation of normal human B-cell precursors is absolutely dependent on BM stromal cells: linear regression analysis was used to compare transplant BM stromal cell CD106 expression with the ability to support B-cell precursor proliferation. As shown in Fig 4A, the expression of CD106 was linearly related to the recovery of CD19+ cells on day 7 ( R = .459, P = .07). However, this relationship was lost by day 14 (Fig 4B, R = .l1 8, P = .66). Likewise, no linear relationship existed on day 21 ( R = .145, P = .58) (data not shown). When CD54 expression by transplant BM stromal cells was compared with the recovery of CD19' B-cell precursors on days 7 ( Fig  4C) and 14 (Fig 4D) , no linear relationship was observed.
Adhesion of B-cell precursors to transplant BM stromal cells is correlated to the proliferation of B-cell precursors. Because CD106 expression was correlated to B-cell precursor adhesion (Fig 3A) and proliferation (Fig 4A) , we analyzed the relationship between the ability of transplant BM stromal cells to support the adhesion and proliferation of Bcell precursors. The data in Fig 5 show a linear relationship between adhesion of B-cell precursors and the maximum recovery of CD19+ cells on either day 7, 14, or 21 ( R = S38, P = .03). Weaker correlations between adhesion and proliferation of B-cell precursors were observed on days 7 ( R = .263, P = .14), 14 ( R = .377, P = .12), and 21 ( R = ,322, P = .16).
DISCUSSION
Studies of human B-cell ontogeny have been facilitated by the development of BM stromal cell-dependent cultures that support the in vitro growth of normal B-cell precursors?6'8 Adhesion of normal B-cell precursors to BM stromal cells is primarily mediated by CD49dCD29 and CD106.9-LL MoAb to murine CD49dCD29" and CD106" block B lymphopoiesis in Whitlock-Witte cultures, and MoAb to the CD49d and CD29 subunits of human VLA-4 inhibit the growth of TdT+ lymphoid progenitors? However, evidence implicating CD106 in functional events beyond the initial adhesion of human B-cell precursors to BM stromal cells has not been reported. The delay in B-cell reconstitution after BMT has been known for some time.I4 Given the lack of a unifying mechanistic model to explain this delay, we hypothesized that an abnormality in BM stromal celVB-cell precursor interactions may be involved. The rationale underlying this hypothesis rests partially on the large body of evidence identifying the toxic effects of infectious agents, chemical agents, and ionizing irradiation on the BM micro- envir~nment.~~ Therefore, we reasoned that one consequence of this BM damage might be an alteration in the capacity of BM stromal cells to support the adhesion and growth of Bcell precursors. This could, in turn, delay the appearance of normal B-cell numbers in peripheral blood.
Although normal human B-cell precursors can be grown on BM stromal the technology has not developed to the point where limiting numbers (ie, the number of Bcell precursors that would be present in BM aspirates at day 28 (post-BMT) can be routinely grown. We therefore DllTEL AND LEBEN compared the functional integrity of BM stromal cells established from BMT recipients and normal donors for their adhesion molecule expression and the capacity to support the adhesion and growth of normal B-cell precursors. The strategy we employed was to establish BM stromal cell CUItures from patients who had received allogeneic or autologous BM transplants for BCP-ALL, NHL, or HD. We SUCcessfully established BM stromal cells from 27 of 73 patients, but observed no relationship between successful establishment and type of transplant, underlying disease, or recipient age. One explanation for the failure to establish confluent BM stromal cell cultures may have been damage from irradiation andor chemotherapy, resulting in extreme hypocellularity in the BM aspirates used to initiate the cultures (see below).
Although the hypocellularity of recipient marrow at 21 to 28 days post-BMT resulted in a consistent delay in the establishment of transplant BM stromal cell cultures compared with normal donor BM, the cell surface phenotype was indistinguishable, with the exception of CD106. The level of CD106 was significantly lower on BMT recipient stromal cell cultures compared with normal donors (Fig 1 ) , but there was no apparent abnormality in CD106 isoform expression (Fig 2) or regulated response to cytokine stimulation ( Table 1) . The reduced CD106 expression has several possible explanations including: outgrowth of a subpopulation of BM stromal cells expressing low CD106, senescence of transplant BM stromal cells, or inheritable changes in BM stromal cell gene expression secondary to DNA damage caused by irradiation or chemotherapy. The former possibility seems unlikely for several reasons. First, 16 distinct cell surface antigens identified by MoAb were identical in expression on normal and transplant BM stromal cells, with the exception of CD106. In addition, cytokine responsiveness based on regulated expression of CD106 was essentially the same (Table l) , and both normal and transplant BM stromal cells expressed the 7 Ig domain isoform of CD106 (Fig 2) . Thus, by the criteria of constitutive expression of many distinct gene products, and cytokine-regulated expression of CD106, the predominant cellular component of normal and transplant BM stromal cell cultures was the same. We cannot rule out the possibility that small numbers of macrophages were present in some of the stromal cell cultures, and macrophage-derived cytokines (eg, IL-1) can regulate CD106 expression. Although we did not monitor macrophage content in all the BM stromal cell cultures used in the current study, our previous studies have shown that CD 1 1 b+/HLA-DR+ macrophages are very low in number or undetectable in second passage BM stromal cells."
Transplant BM stromal cells deficient in the capacity to support the adhesion and growth of B-cell precursors may have been senescent, due to a potentially increased number of doublings required to generate confluent monolayers. We tried to control for this possibility by classifying our BM stromal cell cultures using criteria previously used to categorize aging fibroblasts in vitro.?' We only used normal and transplant BM stromal cell cultures that displayed morphologic characteristics of mitotic and postmitotic fibroblasts; that is, fibroblasts able to adhere, spread, and form confluent monolayers? Transplant and normal BM stromal cell cul- observations. Analysis of transplant and normal BM stromal cells for CD106 and CD54 expression was conducted the same day the Bsell precursor proliferation assay was initiated.
tures were both used at second or third passage and displayed indistinguishable morphological characteristics and growth kinetics. The optimal approach for initiation and establishment of stromal cell cultures would employ positive selection (perhaps using anti-CD106 MoAb) of BM stromal cell precursors (ie, the adventitial reticular cells that adhere to tissue culture flasks and undergo expansion), and subsequent plating of equal numbers in culture on day 0. Transplant BM stromal cell cultures expressing reduced levels of CD106 may have acquired genetic changes induced by irradiation or chemotherapy. The reduced expression of cell surface CD106 (Fig 1) could reflect alterations in transcription, translation, or protein stability. CD106 expression is regulated differently in individual cell types. For example, CD106 is only expressed on endothelial cells following cytokine ~timulation.~~*~' Alternatively, BM stromal cellsg"' and follicular dendritic cells3' constitutively express CD106, which can be increased by specific cytokines. Although transcriptional regulation of BM stromal cell CD106 has not been characterized, transcription of CD106 in endothelial cells is known to be regulated by two NF-kB sites within the CD106 promoter.3941 Independent of the mechanism by which CD106 expression is regulated following cytokine stimulation of BM stromal cells, this process does not appear to be grossly altered in stromal cells established from transplant recipients (Table 2) . Thus, the mechanism by which constitutive CD106 expression is reduced in BMT recipient stromal cells remains to be determined.
Although not investigated in the current study, alterations in cytokine production could also be involved. TGF-P downregulates CD106 expression in normal BM stromal cells," and CD106 is constitutively expressed by BM stromal cells established under Dexter culture conditi0ns.4~~~ Thus, overexpression of stromal cell TGF-P could lead to reduced levels of CD106 expression, in addition to exerting a general antiproliferative effect on a variety of lymphohematopoietic cells. It is noteworthy that increased levels of TGF-P production by BM stromal cells from patients with chronic lymphocytic leukemia have been reported.& Our inability to establish transplant BM stromal cell cultures from -60% of BM aspirates may reflect the intrinsic hypocellularity of recipient BM in the first several weeks posttransplant. Indeed, some BM aspirates gave rise to adherent cells with only a limited capacity to grow, thereby yielding partially confluent cultures that could not be expanded for functional studies. The toxic effects of ionizing irradiation on the BM microenvironment are l e g i~n .~~.~' Experiments in the mouse have noted damage to BM stromal cells after irradiation or chemotherapy, manifested as morphologically altered cytoplasmic organelles and plasma membranes, cytoplasmic vacuoles, and nuclear damage.34 Our difficulty in establishing confluent monolayers might find explanation in earlier murine studies. Whereas highdose-irradiated marrow sites showed no evidence of structural damage in situ, significant cell kill was observed after one to two traversals of the cell cycle in High-doseirradiated sites left undisturbed for 6 months showed significant repair of potentially lethal irradiation da1nage.4~ Extrapolating these findings to our study, it is conceivable that some of our transplant BM stromal cell culture failures could reflect an inability to repair irradiation damage that culminated in premature stromal cell death in vitro. Other studies have noted heterogeneity in the radiosensitivity of human BM stromal cell lines (established from a single donor) to low-dose-rate irradiation." Therefore, it would seem highly possible, and even probable, that radiobiologic differences would exist in radiosensitivity and repair capacity of BM stromal cells from different transplant recipients.
In conclusion, our results further illuminate the functional importance of CD106 expression on human BM stromal cells that support the IL-7-dependent growth of human B-cell precursors. We have shown that BM stromal cells isolated from transplant recipients have a reduced expression of CD 106, and this reduction correlates with a reduced capacity to support B-cell precursor adhesion and growth. The reduced CD106 expression could result in a lower threshold of cell signaling events delivered to B-cell precursors through CD49dCD29, leading to a decrease in B-cell precursor proliferation. However, given the array of toxic effects exerted by irradiation and chemotherapy on the BM microenviron~n e n t ,~~ it is almost certain that additional abnormalities exist that compromise the B lymphopoietic supportive capacity of BM stromal cells. For personal use only. on October 22, 2017. by guest www.bloodjournal.org From
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